Red carpet stars have turned heads this awards season with dramatic slim-downs, spotlighting GLP-1 medications like Wegovy and Mounjaro. These weekly injections promise rapid weight loss, but they were designed to fight obesity and its risks—diabetes, heart disease, and early death—by mimicking the appetite-suppressing hormone GLP-1.
Yet, up to 20% of users see minimal results. Research shows initial losses often plateau, with nearly 85% of patients stalling completely, leading to frustration and dropout.
Quitting GLP-1 Drugs Leads to Rapid Regain
Oxford University researchers warn against stopping weight-loss injections. Users regained about a pound monthly post-quit, projected to recover most or all weight in 17-20 months, regardless of prior loss.
Emilly's Success: Hydration and Protein Unlocked Progress
Emilly Murray, 35, a Liverpool nurse and mum-of-three, started Mounjaro in December 2024 at 22st (dress size 30). Her loss slowed near target weight, frustrating her.
She boosted protein and hydration. Water fills the stomach to curb hunger, while dehydration slows metabolism. Despite cold sensitivity from Mounjaro, she persisted and shed another five stone by summer, reaching 9st 2lb (size 6).
Neuroscientist Dr. Rubina Aktar notes GLP-1s slow stomach emptying for prolonged fullness, often reducing fluid intake.
Optimize Your GLP-1 Dosage
A July study of over 100 patients on Mounjaro and Wegovy found 86% achieved major loss on low doses. Strongest results hit at half max (7.5mg vs. starter 2.5mg); high doses (up to 15mg) risk more regain off-drug.
Plateaus may signal need for increase. Prof. Naveed Sattar, metabolic medicine expert at University of Glasgow, asks patients first if they've maxed their dose. "Many stay low longer than trials; if affordable and tolerable, up it when tapering," he says. Apps like Shotlee help track GLP-1 doses precisely.
Pair GLP-1s with Lifestyle Changes
Prof. David Strain, cardiometabolic health expert at Exeter University, stresses GLP-1s as enablers for diet and activity shifts, not solo fixes. Combined approaches outperform either alone.


